Dr Yung Kao
MBBS, MRCP, FAMS, FRACP, FAANMS
For patients/carers
For doctors
MBBS, MRCP, FAMS, FRACP, FAANMS
Locations
Clinical interests
- Prostate cancer
- Liver cancer
- Thyroid cancer
Treatment techniques
- Theranostics
- Radiopharmaceutical therapy
Languages
Fluent
- English
- Mandarin / 普通话
Biography
Dr Kao is a world-leading Nuclear Medicine Physician who is internationally renowned for his expertise in predictive dosimetry for radiopharmaceutical therapy.
His pioneering work on personalised tomographic radiation prescription has been widely adopted around the world as the standard of care, transforming radiopharmaceutical cancer therapy from a palliative treatment into one of today's curative modalities. Dr Kao's extensive publications in peer-reviewed medical journals on the technical methods of personalised radiopharmaceutical prescription have formed the scientific framework for modern theranostics practice. In 2026, the International Atomic Energy Agency (IAEA) recommended Dr Kao’s scientific technique of personalised predictive dosimetry as the new standard of care for state-of-the-art radiopharmaceutical prescription (Moghrabi et al. Q J Nucl Med Mol Imaging 2026).
Dr Kao continues his cutting-edge clinical research to shape the future of personalised cancer therapy.
More information
- Kao et al. (2026). Correlation of tumor absorbed dose with progression-free survival in metastatic castration-resistant prostate cancer treated with ^177Lu-PSMA. Journal of Nuclear Medicine Technology 2026;54:149-152. https://doi.org/10.2967/jnmt.125.270563
- Kao, Y. H. (2025). Rapid predictive dosimetry is now freely available. Journal of Nuclear Medicine, 66, 1499–1500. https://doi.org/10.2967/jnumed.125.269581
- Kao et al. (2025). Direct correlation of tumor absorbed dose with overall survival in metastatic castration-resistant prostate cancer treated with ^177Lu prostate-specific membrane antigen. Journal of Nuclear Medicine Technology, 53(4), 252–256. https://doi.org/10.2967/jnmt.124.268355
- Kao et al. (2024). First-strike rapid predictive dosimetry and dose response for ^177Lu-PSMA therapy in metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine Technology, 52(3), 212–218. https://doi.org/10.2967/jnmt.123.267154
- Kao, Y. H. (2023). A simplified general schema for rapid single time-point marrow predictive dosimetry. Nuclear Medicine Communications, 44, 1187–1188. https://doi.org/10.1097/MNM.0000000000001709
- Kao, Y. H. (2022). Single time point tumour dosimetry assuming normal distribution of tumour kinetics. Journal of Nuclear Medicine, 63(Supplement 2), 803.
- Kao, Y. H. (2014). Dosimetric theory for tumor-to-lung shunt fraction calculation in yttrium-90 radioembolization of noncirrhotic livers. Nuclear Medicine Communications, 35, 331–332. https://doi.org/10.1097/MNM.0000000000000040
- Kao, Y. H. (2014). General theory of predictive dosimetry for yttrium-90 radioembolization to sites other than the liver. CardioVascular and Interventional Radiology, 37, 1114–1117. https://doi.org/10.1007/s00270-013-0805-1
- Kao, Y. H., et al. (2013). Post-radioembolization yttrium-90 PET/CT—Part 2: Dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Research, 3, 57. https://doi.org/10.1186/2191-219X-3-57
- Kao, Y. H., et al. (2012). Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective ^90Y radioembolization. Journal of Nuclear Medicine, 53, 559–566. https://doi.org/10.2967/jnumed.111.09829
Explore more
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.